12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

ARCHITECT Galectin-3 test regulatory update

BG Medicine disclosed in its 2012 earnings that partner Fujirebio Inc. (Tokyo, Japan) withdrew a 510(k) application for the ARCHITECT Galectin-3 test, an automated version of BG Medicine's BGM Galectin-3 test that is marketed as an aid in assessing the prognosis of patients diagnosed...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >